Navigation Links
Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
Date:11/6/2008

KVISTGARD, Denmark, November 6 /PRNewswire-FirstCall/ -- Bavarian Nordic has completed a clinical safety report from a large Phase II study with IMVAMUNE(R) in HIV infected subjects that confirms the excellent safety profile of IMVAMUNE(R). Within the next few days the safety report of this study will be submitted to the FDA and this will trigger a USD 25 million milestone payment under the RFP-3 contract. The clinical safety report constitutes a major part of the data package that will be used to potentially support the use of IMVAMUNE(R) in a declared emergency.

In support of using IMVAMUNE(R) as a smallpox vaccine in individuals otherwise contraindicated to receive conventional vaccinia vaccines, Bavarian Nordic has performed a large Phase II study in HIV infected subjects with CD4 counts between 200 and 750 cells/microl to compare the safety to healthy subjects.

The safety report from this study, which represents an essential part of the EUA data package, includes safety data from over 300 HIV infected and 86 healthy subjects, all of whom had no history of prior smallpox vaccination. The low number of adverse events confirmed the favourable safety profile of IMVAMUNE(R) in vaccinia-naive HIV infected subjects with varying degrees of immune suppression. Indeed, there was no difference in adverse events between the healthy and HIV infected subjects, even in the most immune compromised patients (CD4 counts greater than or equal to 200-350 cells/microl). IMVAMUNE(R) has now been tested in more than 2,200 people in 11 completed or on-going clinical studies, which includes a large proportion (more than 750) of immune-compromised people i.e. HIV infected or diagnosed with Atopic Dermatitis (AD) who are excluded from vaccination with traditional smallpox vaccines.

The complete data set from this trial is expected to be reported in the second half of 2009. The final report will include data on immunogenicity as well as long-term (6-month) safe
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
2. Bavarian Nordic Enters Clinical Trials with HIV Multiantigen Vaccine
3. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
4. Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
5. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
6. Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
7. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
8. Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study
9. BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test
10. Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
11. MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014  AnaptysBio, Inc., a ... antibodies, today announced the appointment of Marco ... Londei will lead the preclinical and clinical development ... "We are pleased to welcome Dr. Londei to ... , President and Chief Executive Officer of AnaptysBio. ...
(Date:10/20/2014)... , Oct. 20, 2014   Mary,s Medicinals ... Caring, is a 4-Star Sponsor of Operation Grow4Vets ... with unique products, programs and services to assist them ... Key Facts: , An ever-increasing ... a safe and effective treatment for pain, Post-traumatic Stress ...
(Date:10/19/2014)... , Oct. 20, 2014 CTI BioPharma Corp. ... will report its third quarter 2014 financial results on ... U.S. financial markets. Following the announcement, members of the ... discuss the results and provide a general corporate update ... the event can be obtained as follows: ...
Breaking Medicine Technology:AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2
... FORT WORTH, Texas, Sept. 30 Wound Care,Innovations, ... (OTC,Bulletin Board: WNDM), announced today that it will ... and Economical Realities in Boston. This,seminar is presented ... Wound Clinic, Podiatry Today and producers of the ...
... Sept. 29 Obese school-age,kids and teens can ... they,participate in medium- to high-intensity behavioral management programs,according ... Agency for Healthcare,Research and Quality., Children in ... for more than 25 hours, usually once or ...
Cached Medicine Technology:Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R) 2Behavioral Modification Programs Help Obese Children Manage Their Weight 2Behavioral Modification Programs Help Obese Children Manage Their Weight 3
(Date:10/20/2014)... Myoderm announced today ... of their CentralSource service. Matthew will ... turnkey drug sourcing, distribution, and management service for ... years of industry experience, in both business development ... of their international success to help clients manage ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Final Cut Pro ... release of the Citrus theme for FCPX filmmakers . ... use to describe the Citrus theme” Says Christina Austin, CEO ... to look so professional.” , Citrus comes with all the ... the template are: four transitions for added style, a title ...
(Date:10/20/2014)... Spring, Maryland, USA (PRWEB) October 20, 2014 ... or to track interventions? Here comes a wonderful app ... mobile app development company helped its client ... Intervention more efficiently. The app is designed for iOS ... and iPod touch. This app is optimized for iPhone ...
(Date:10/19/2014)... This report provides comprehensive information on ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ... late-stage and discontinued projects. , Partial Seizures are ...
(Date:10/19/2014)... 19, 2014 Visual Impact Frequency ... just been released to the public generating a ... building and fitness community. The commotion surrounding the ... Vin Delmonico prompting an investigative review. , "Many ... what is commonly known as a training 'plateau' ...
Breaking Medicine News(10 mins):Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2
... , , BOSTON, Sept. 14 Americans ... Currently, there are five million people living with this disease ... an important role in the cause and prevention of Alzheimer,s ... can do to stave off this devastating illness. , ...
... years later, study finds , MONDAY, Sept. 14 (HealthDay ... go into combat are more likely to develop high ... serve in supporting roles, a new military study finds. ... a unique risk factor for newly reported hypertension," Nisara ...
... MONDAY, Sept. 14 (HealthDay News) -- Decades of steady progress ... with a new study showing that only 7.5 percent of ... heart disease risk factors. , The continuing U.S. obesity epidemic ... researchers added. , "Our results raise the concern that a ...
... up chances of other cancers, clots , MONDAY, Sept. ... high risk for developing breast cancer do reduce their ... a new analysis suggests. , That was the conclusion ... randomized clinical trials and a head-to-head assessment of the ...
... ... St. Louis , ... 15, 2009 -- , , ,WHO: American Association of Radon Scientists and Technologists, , ,WHAT: ... Union Station Marriott (near Scottrade Center) ,One St. Louis Union Station, , ,WHY: Radon ...
... Sept. 14 Misonix, Inc. (Nasdaq: MSON ), ... in Europe is used for the ablation of tumors and ... patient, who wishes to remain anonymous, donated the majority of ... Fe, NM, to purchase a SonicOne(R) Ultrasonic Wound Cleansing and ...
Cached Medicine News:Health News:Senior Living Residences Launches Innovative Nutrition Program to Promote Cognitive Health and Lower the Risk of Alzheimer's Disease 2Health News:Combat Exposure Tied to Chronic High Blood Pressure 2Health News:Most Adult Americans at Some Risk for Heart Disease 2Health News:Most Adult Americans at Some Risk for Heart Disease 3Health News:Medications That Lower Breast Cancer Risk Carry Other Dangers 2Health News:Medications That Lower Breast Cancer Risk Carry Other Dangers 3Health News:21st International Radon Symposium 2Health News:Misonix Equipment Funded By Anonymous Patient Donation 2Health News:Misonix Equipment Funded By Anonymous Patient Donation 3
... Single use curved circular stapler ... titanium staples., ,The Auto ... is used throughout the alimentary ... end-to-end, end-to-side and side-to-side anastomoses ...
... is a two-site immunoradiometric assay (IRMA) for ... polyclonal antibodies to human calcitonin have been ... for well-defined regions on the calcitonin molecule. ... in human serum. For in vitro ...
Calcitonin RIA Kit...
... digital camera system by KARL STORZ, a ... camera systems. Digital Source Sampling technology, applied ... fully digital transfer of information with no ... as well as loss-free data storage on ...
Medicine Products: